Australia markets closed

AVXL Jul 2022 25.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
As of 10:25AM EDT. Market open.
Full screen
Previous close0.1500
Open0.1500
Bid0.0000
Ask0.0000
Strike25.00
Expiry date2022-07-15
Day's range0.1500 - 0.1500
Contract rangeN/A
Volume2
Open interestN/A
  • Zacks

    Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

    NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H

  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

    Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter end